Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG

Yifan Zhou, Qiao Huang, Tingting Lu, Xiaobo Sun, Ling Fang, Zhengqi Lu, Xueqiang Hu, Allan Kermode, Wei Qiu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.

Original languageEnglish
Pages (from-to)71-73
Number of pages3
JournalJournal of Clinical Neuroscience
Volume38
DOIs
Publication statusPublished - 1 Apr 2017

Fingerprint

Myelin-Oligodendrocyte Glycoprotein
Azathioprine
Multiple Sclerosis
Immunoglobulin G
Pediatrics
Methylprednisolone
Therapeutics
Magnetic Resonance Imaging
Antibodies

Cite this

Zhou, Yifan ; Huang, Qiao ; Lu, Tingting ; Sun, Xiaobo ; Fang, Ling ; Lu, Zhengqi ; Hu, Xueqiang ; Kermode, Allan ; Qiu, Wei. / Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG. In: Journal of Clinical Neuroscience. 2017 ; Vol. 38. pp. 71-73.
@article{a793aadb5be44699a0b42521c74d8a63,
title = "Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG",
abstract = "There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.",
keywords = "Azathioprine, MOG-IgG, Multiple sclerosis, Pediatric",
author = "Yifan Zhou and Qiao Huang and Tingting Lu and Xiaobo Sun and Ling Fang and Zhengqi Lu and Xueqiang Hu and Allan Kermode and Wei Qiu",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.jocn.2016.12.022",
language = "English",
volume = "38",
pages = "71--73",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",

}

Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG. / Zhou, Yifan; Huang, Qiao; Lu, Tingting; Sun, Xiaobo; Fang, Ling; Lu, Zhengqi; Hu, Xueqiang; Kermode, Allan; Qiu, Wei.

In: Journal of Clinical Neuroscience, Vol. 38, 01.04.2017, p. 71-73.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG

AU - Zhou, Yifan

AU - Huang, Qiao

AU - Lu, Tingting

AU - Sun, Xiaobo

AU - Fang, Ling

AU - Lu, Zhengqi

AU - Hu, Xueqiang

AU - Kermode, Allan

AU - Qiu, Wei

PY - 2017/4/1

Y1 - 2017/4/1

N2 - There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.

AB - There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.

KW - Azathioprine

KW - MOG-IgG

KW - Multiple sclerosis

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=85009759051&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2016.12.022

DO - 10.1016/j.jocn.2016.12.022

M3 - Article

VL - 38

SP - 71

EP - 73

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

ER -